Skip to main content

Merck: Investigational drug did not meet endpoints

6/5/2009

WHITEHOUSE STATION, N.J. Merck & Co. said Friday that preliminary results for the pivotal phase III study of rolofylline (MK-7418), the company's investigational medicine for the treatment of acute heart failure, show that rolofylline did not meet the primary or secondary efficacy endpoints.

"Advances to help patients with acute heart failure, a disease that is the leading cause of hospitalization for patients over age 65 and that is associated with a high rate of mortality, have long been elusive," said Dan Bloomfield, M.D., executive director, cardiovascular research, Merck Research Laboratories. "These results are disappointing because we had been hopeful that blocking the adenosine A1 receptor with rolofylline would prove to be a useful new approach for these patients.

The primary endpoint for the phase III study were that the drug would would improve symptoms of acute heart failure (compared with placebo). Secondary endpoints included reducing the risk of death, renal re-hospitalization 60 days after treatment and reducing the incidence of persistent kidney impairment.

Rolofylline was acquired by Merck through NovaCardia, which Merck purchased in 2007. Results from the PROTECT pilot study, presented at previous medical meetings and published in 2008, had showed an overall trend toward efficacy (more patients with improved shortness of breath, fewer patients with worsening renal function and/or worsening heart failure).

While Merck will continue to analyze the data with outside experts, the company will not file applications for regulatory approval this year. The results from this study will be presented at a medical meeting later this year.

Merck's late-stage pipeline of investigational medicines for cardiovascular disease includes MK-524A (approved in some markets outside the U.S.), MK-524B, ezetimibe/atorvastatin, and anacetrapib (MK-0859) for atherosclerosis, and vernakalant for atrial fibrillation.

X
This ad will auto-close in 10 seconds